Fundraising Fox

Vivacelle Bio

Chicago, US · Founded 2013 · Delaware corporation · 1 known investors

vivacellebio.com ↗

Vivacelle Bio develops phospholipid nanoparticle therapies (VBI-S and VBI-1) that restore intravascular volume and redirect excess nitric oxide to treat hypovolemia in patients with septic shock or severe blood loss. The company is running a Phase III trial for its lead asset VBI-S in septic shock patients across U.S. sites.

BiotechHealthtechMedical Devices

Founders & leadership

Vivacelle Bio was founded in 2013 by Cuthbert Ormand Simpkins, Diane Simpkins, and Conrad Epting.

COCuthbert Ormand Simpkins
Cuthbert Ormand SimpkinsCo-founder
DS
Diane SimpkinsinCo-Founder & Treasurer, Board of Directors
CE
Conrad EptinginFounding Member / Scientific Consultant
HDHarven DeShield
Harven DeShieldinExecutive
SK
Stephen KeithExecutive
PPaul
PaulCEO/CFO
SN
Stephen N. KeithFormer CEO

Board

RD
Ron DamperBoard director

Investors · 1

2Flo Ventures✓ verifiedChicago · $400 – $1K

Reported raises · per SEC filings

Form D private placements

$4.2M disclosed across 2 rounds · 2014–2016

▶$2.9MraisedFeb 2019 · 59 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cuthbert SimpkinsExecutive Officer, Director
  • Ron DamperDirector
  • Diane SimpkinsExecutive Officer, Director
  • Krishna TalluriExecutive Officer
  • Harven DeShieldExecutive Officer, Director
Offering amount
$3.4M
Amount sold
$2.9M
First sale
Aug 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedSep 2016 · 58 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ron DamperDirector
  • Harven DeShieldExecutive Officer, Director
  • Stephen KeithExecutive Officer, Director
  • Cuthbert Ormand SimpkinsExecutive Officer, Director
  • Diane SimpkinsExecutive Officer, Director
Offering amount
$1.3M
Amount sold
$1.3M
First sale
Jan 2014
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Vital Biosciences Inc.7 shared keywordsVitalBio develops the VitalOne, a diagnostic device that delivers comprehensive lab-grade blood test results in minutes from a small blood sample, using robotics, biochemistry, computer vision, and microfluidics. It targets healthcare providers and patients seeking point-of-care diagnostic testing.
Globus Medical4 shared keywordsGlobus Medical designs and manufactures spine, trauma, and robotic surgical products for the orthopedic medical device market. The company serves hospitals and surgical centers globally.

Companies competing with Vivacelle Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$251.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Vivacelle Bio do?
Vivacelle Bio develops phospholipid nanoparticle therapies (VBI-S and VBI-1) that restore intravascular volume and redirect excess nitric oxide to treat hypovolemia in patients with septic shock or severe blood loss. The company is running a Phase III trial for its lead asset VBI-S in septic shock patients across U.S. sites.
Who founded Vivacelle Bio?
Vivacelle Bio was founded by Cuthbert Ormand Simpkins, Diane Simpkins, Conrad Epting in 2013.
Who are Vivacelle Bio's investors?
Vivacelle Bio's investors include 2Flo Ventures.
How much funding has Vivacelle Bio raised?
Vivacelle Bio has disclosed $4.2M raised across 2 rounds.
Where is Vivacelle Bio headquartered?
Vivacelle Bio is headquartered in Chicago, US.